孕间期与孕期生活方式干预(INTER-ACT):一项随机对照试验
INTER-ACT 研究在比利时6家佛兰德斯医院招募既往妊娠期体重增长过多的女性,随机分为面对面辅导联合电子健康应用干预组与常规照护组,评估孕间期至再次妊娠期间生活方式干预对妊娠并发症复合结局的影响。干预未显著降低复合结局(OR 1.29,95%CI 0.85-1.96,P=.23),但事后分析显示两组中随访依从性均与复合结局风险降低相关。
要点
- 干预组与常规照护组的妊娠并发症复合结局无显著差异(OR 1.29,95%CI 0.85-1.96,P=.23)。
- 事后分析中,干预组随访依从者复合结局风险降低(OR 0.50,95%CI 0.26-0.98,P=.04)。
- 事后分析中,对照组随访依从者复合结局风险亦降低(OR 0.48,95%CI 0.26-0.90,P=.02)。
核心结论
- INTER-ACT 干预未能降低既往妊娠期体重增长过多女性的妊娠并发症复合结局发生率,但孕期随访依从性与两组复合结局风险减半相关。
研究设计与样本
- 前瞻性、多中心随机对照试验,在比利时6家佛兰德斯医院的基层与二级医疗机构于前次妊娠后6周内招募参与者。
- 共筛查8897例妊娠期体重增长过多的女性,随机化1450例,其中390例随后发生单胎妊娠,干预组193例、常规照护组197例。
- 干预包括面对面辅导课程与电子健康应用,聚焦营养、体力活动和心理健康。
- 主要结局为妊娠并发症复合结局,包括妊娠期高血压、妊娠期糖尿病、剖宫产和大于胎龄儿。
- 按80%统计效能和0.05显著性水平,每组需招募250例后续分娩女性以检测复合结局发生率的显著差异。
主要发现
- 招募时间为2017年5月至2019年4月。
- 生活方式干预未显著降低复合结局(OR 1.29,95%CI 0.85-1.96,P=.23),也未显著降低次要结局。
- 事后亚组分析显示,干预组中随访依从者复合结局风险降低(OR 0.50,95%CI 0.26-0.98,P=.04)。
- 事后亚组分析显示,对照组中随访依从者复合结局风险亦降低(OR 0.48,95%CI 0.26-0.90,P=.02)。
- 两组基线社会人口学特征总体可比。
临床怎么用
- 作者认为孕期随访依从性是关键,无论分组如何,持续参与均可能带来获益。
- 作者建议未来试验应聚焦提高依从性,并探索生活方式干预对不同体质指数范围女性妊娠结局的影响,尤其是孕前和孕间期。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lifestyle interventions prior to conception hold potential to reduce pregnancy-related complications, although this has been constrained due to challenges in reaching preconception women. OBJECTIVE: We aim to study the effectiveness of the interpregnancy and pregnancy lifestyle intervention (INTER-ACT) lifestyle intervention spanning through the interpregnancy and subsequent pregnancy periods in women with a history of excessive gestational weight gain on reducing pregnancy complications. STUDY DESIGN: The Interpregnancy Coaching for a Healthy Future (INTER-ACT) study is a prospective, multicenter randomized controlled trial. METHODS: Participants were recruited within 6 weeks after a previous pregnancy from a combination of primary and secondary healthcare facilities across 6 Flemish hospitals in Belgium. The INTER-ACT intervention involved face-to-face coaching sessions and an E-Health application aimed at promoting healthy behaviors, including nutrition, physical activity, and mental wellbeing. The primary outcome was a composite of pregnancy complications including pregnancy-induced hypertension, gestational diabetes, cesarean section, and large for gestational age infants. To identify a significant difference between the intervention and control group in the incidence of composite outcome, with a statistical power of 80% and significance level of 0.05, 250 women with subsequent delivery in each group needed to be recruited. RESULTS: Participants were recruited from May 2017 through April 2019. Of 8897 women with excessive gestational weight gain, 1450 were randomized. Three hundred and ninety subsequently experienced singleton pregnancy, with 193 in the intervention group and 197 in usual care. Baseline sociodemographics were generally comparable between groups. The lifestyle intervention did not significantly reduce the composite outcome (odds ratio, 1.29; 95% confidence interval, 0.85-1.96; P=.23) or secondary outcomes. In a post hoc subanalysis, we found that adherence to follow-up during the subsequent pregnancy was associated with a reduced risk of the composite outcome in both study arms (intervention group: odds ratio, 0.50, 95% confidence interval, 0.26-0.98, P=.04; control group: odds ratio, 0.48, 95% confidence interval, 0.26-0.90, P=.02), suggesting a potential benefit of continued engagement regardless of allocation. CONCLUSION: The INTER-ACT intervention did not result in a lower composite outcome rate in women with previous excessive gestational weight gain. However, adherence during pregnancy was key, halving risks in both study arms. Future trials should focus on improving adherence and exploring the impact of lifestyle interventions on pregnancy outcomes in women across diverse body mass index ranges, particularly in the preconception and interpregnancy periods.
引用
- Bogaerts A, Van Uytsel H, Ameye L, et al. Interpregnancy and pregnancy lifestyle intervention (INTER-ACT): a randomized controlled trial. Am J Obstet Gynecol. 2025. PMID: 40466885. doi:10.1016/j.ajog.2025.05.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。